The company's focus is on the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases. Their technologies also hold the promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention.
Keystone Nano has an exclusive license to Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles that they call Molecular Dots (MDs). These Molecular Dots can encapsulate drugs and/or fluorescent molecules.
The combination of a protected blood transporting nanocarrier system and a tumor specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive and dynamic anticancer market, where drug delivery systems will gain increasing importance over the coming years.
Living Cell is developing cell-based products to treat life threatening human diseases. The company has developed proprietary nanobiocapsules which allow encapsulated pig insulin producing cells, DiabeCell, to be implanted without the use of toxic immune suppressive drugs.
NanoMedical Systems (NMS) is a startup company, which will commercialize the patented research of Dr. Mauro Ferrari at the University of Texas Health Science Center in Houston, a sponsored research site and a source of licensed IP for NMS. The company's Personalized Molecular Drug-delivery System (PMDS) is a small drug delivery device that is implanted subcutaneously (just under the skin) for slow and consistent release of a therapeutic agent over many weeks or months. A nanochannel delivery system (nDS) embodied on a silicon chip regulates the flow of therapeutic molecules.
An early stage therapeutic drug company, NanoVector Inc. is commercializing a patent pending nanoparticle drug delivery system developed at North Carolina State University. The NanoVector nanoparticle is a plant virus. Central to our technology, this virus, which has evolved over millions of years, has several inherent characteristics essential for a successful nanoparticle delivery system and superior to any designed and engineered by humans.
OZ Biosciences creates, develops and produces innovative tools based on drug delivery systems for the worldwide scientific community and pharmaceutical industry. OZ Biosciences focuses on technologies for the delivery of bioactive materials into living organisms.
PDS Biotechnology Corporation is a biopharmaceutical company applying the company's platform Versamune nanotechnology to a new class of safe, simple, potent and targeted immunotherapies for the treatment of cancer and infectious diseases.
PolyRemedy, Inc. manufactures robotic systems for the fabrication of nano-material based wound dressings at the point-of-care, allowing wound care clinicians to deliver easily and cost-effectively customized wound care on-demand for each patient's unique wound.
Rexahn and the University of Maryland, Baltimore (UMB) Center for Nanomedicine & Cellular Delivery (CNCD), are jointly pursuing the development of water-soluble nano-polymers for targeted delivery of anticancer drugs.